A China-based healthcare fund focuses on global growth opportunities. The firm is based in Shanghai with several offices in the USA. In addition, the firm launched a sister fund that is focused on Seed to Series A opportunities in healthcare. Typical early-stage investment through the firm is US $5-10M. The firm prefers to lead in a financing round but is also open to co-investing. The firm is currently seeking opportunities from the US, China, Europe and Israel.

When it comes to early-stage healthcare investments, the firm is extremely opportunistic across sectors. The firm’s focus is divided between 80 percent pharma and biotech, reserving 20 percent for devices, digital health and healthcare services. In terms of disease areas, the firm prefers technologies targeting large unmet medical need and is less interested in rare diseases. The firm is seeking opportunities in Seed or Series A stage. In the Diagnostics space, the firm only looks for products in the commercial stage from China.

The firm is looking for experienced teams with strong sector expertise. As a China-based fund, the firm seeks to add value in the Chinese market through joint venture, registration expertise, and distribution channels.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A group of globally acting venture capital and private equity firms with an operating track record that span decades, operate globally with dedicated Life Science venture capital funds with a global footprint. The group’s Life Science Venture arm is looking to provide seed, venture and growth capital to companies in the life science space. The firm’s investment size is highly variable depending on the stage and financial needs of each company and the firm has no target number of investments it plans to make over the next 6-9 months. The firm is willing to consider investments located globally.

The firm is a dedicated provider of venture capital to the international pharmaceutical, medical technology and healthcare diagnostics industries, hence looking to invest in companies in sectors of Medical devices, Diagnostic Tools and Platforms, and Specialty Pharmaceuticals that are later stage with strong in human data (Phase IIb and III or on the market) and have very little regulatory risk. The firm’s most recent Life Science Venture Capital Fund focuses on a new investment approach to developing pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies that are anywhere from 12-18 months to IND to proof of concept (Phase IIa). The fund is currently most interested in small molecule therapeutics or IND-ready biologics for indications of metabolic disease, diseases of the blood, inflammation, and oncology. The firm is also willing to invest in highly differentiated biological compounds if compelling opportunities arise. The firm is also less inclined to invest into orphan indication.

The firm’s requirements for management teams vary on a case by case basis and the firm is open to discussion in this area.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA fund seeks to in-license 4-6 IND-ready assets and develop them through Phase 2b. After proof-of-concept is established, the firm will seek to exit. Roughly 90% of the fund will be used to fund development, with clinical trials carried out by the firm. They are particularly interested in therapeutics falling in the sectors of neuroscience and immunology.

The firm is seeking small molecules and biologics in the areas of neuroscience and immunology that can improve patient lives. The firm does not consider drugs for highly crowded spaces, for example oncology or disease-modifying drugs for Alzheimer’s. Levadopa-induced dyskinesia in Parkinson’s and ataxia have been areas of interest, and they will consider therapeutics for orphan and rare diseases. Drug platforms addressing self-similar indications/targets are also of interest.

The firm looks for IND-ready drugs that can be developed or re-purposed, and will conduct a thorough due diligence taking 6 months to a year. The opportunity should have a clear regulatory and development pathway and good prospects for an exit within 4 years of acquisition. With strong scientific backgrounds themselves, the firm respects the expertise of the innovators. The firm will work with founders to arrange a deal, and are open to negotiating option agreements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in the USA invests in seed and early-stage digital health and therapeutic companies. The typical investment size for seed investment ranges from $500K to $1M (usually in equity or capped, convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based in the United States. The firm is actively seeking new investment opportunities.

The firm is actively seeking new investment opportunities in the digital health sector and areas of interest include: Precision medicine, digital therapeutics, combination data products, scalability solutions and clinical trial management solutions.

The firm often leads financings and takes a board seats. They prefer to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with several offices in Western Europe specializes in early-stage and growth capital investments in the Technology and Life Sciences sectors. The firm has approximately $1B AUM and is currently investing out of a dedicated Life Sciences fund. Depending on the stage of the company, the firm can allocate up to $15M over the life of the investment. The firm can also lead or co-lead financing rounds of up to $30M or higher with syndication. The firm focuses on European companies but will consider US-based companies with activities in Europe. The firm is actively seeking new investment opportunities.

In the life sciences sector, the firm in therapeutics, medical technology, diagnostics, and digital medicine, and is opportunistic in terms of subsectors and indications. In therapeutics, the firm mainly focuses on early-stage companies with preclinical proof of concept data or about to enter the clinic, with a preference for companies developing highly innovative technology platforms. In diagnostics and medtech, the firm prefers companies with product candidates (with strong IP protection) approaching regulatory approval or companies who have already launched a first product. In digital medicine, the firm looks for data-driven technologies being applied clinically to drive meaningful change in patient outcomes.

The firm typically requests a board seat and looks for a strong and experienced management team, but will also support highly talented fledgling entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical arm of a Japan conglomerate with multiple business operations, including a USA-based licensing and clinical development office and a Japan-based sales division, is seeking to form partnerships and in-licensing relationships regarding early stage assets in its key indication areas. These partnerships are highly flexible, and may involve the firm contributing personnel, sharing studies and research tools, or providing research expense funding.

The firm is interested in early-stage, first-in-class, orally active small molecule NCEs. The firm seeks assets in the following key areas: metabolic disease (type 2 diabetes and its complications, dyslipidemia, NASH, and energy metabolism in Alzheimer’s disease), infectious disease (functional cures for HIV and Hepatitis B), cardiovascular disease (CHF, peripheral arterial disease and pulmonary arterial hypertension), autoimmune disease (multiple sclerosis, lupus, IBD, systemic scleroderma, and organ fibrosis). Additionally, the firm is interested in sarcopenia & cachexia, chronic kidney disease, pain (peripheral targets), and osteoporosis (osteogenesis only). As well as drugs, the firm is interested in drug targets in these disease areas. The firm is open to forming partnerships regarding very early stage assets, at or prior to the lead optimization phase.

For in-licensing for the Japan market, the firm is focused on renal diseases, dermatology and allergic diseases.

The firm also invests in drug discovery technologies and research tools such as: technologies related to translational research using cell culture, isolated cellular organelles and related mechanisms; HTS technologies; protein structure analysis; chemical biology, chemical synthesis, and chemical libraries; biophysical tools; in silico technologies; biomarkers and bioinformatics screening, biomarker research, and compound libraries.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices throughout Europe recently raised a new fund of EUR 80 million in 2019, and invests alongside a network of over 200 private investors across several industries including the Life Sciences. The firm and its investors typically co-invest with other institutional investors for Life Science investments. The firm prefers to invest in later rounds where no further dilution will occur before an exit. The firm and its network typically allocate €1-5M (in equity/convertible loan) over the life of an investment. Normally each investor in the firm’s network invests between €50K and €2M. The firm primarily invests in companies that are based in the D-A-CH region where the firm has a strong footprint, but will consider compelling opportunities globally. The firm is actively seeking new investment opportunities.

The firm makes highly selective investments in medical devices, diagnostics and in enabling technologies in the biotech sector, including genomic and proteomic sequencing. The firm is currently more interested in diabetes, CNS, and oncology but is generally open to all indications. For medical devices, the firm looks for devices that have some proof-of-concept and is agnostic in terms of technology types.

The firm prefers to co-invest with other institutional Life Science investors, particularly for opportunities outside the D-A-CH region; it is preferred that companies based elsewhere have a lead investor in place before approaching the firm.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.